Talazoparib is a medication that belongs to a class of drugs called PARP inhibitors. It works by blocking an enzyme that helps repair damaged DNA in cancer cells, which can help stop cancer cells from growing and dividing. In this trial, it is being studied for treating prostate cancer that has specific genetic mutations.

Enzalutamide is a hormone therapy medication used to treat prostate cancer. It works by blocking the effects of testosterone and other male hormones that can stimulate prostate cancer growth. This medication helps to slow down or stop the growth of prostate cancer cells.

Metastatic Castration-sensitive Prostate Cancer – A condition where prostate cancer has spread beyond the prostate gland to other parts of the body, but still responds to treatments that lower testosterone levels. In this type of cancer, the tumor cells continue to be dependent on male hormones (androgens) for their growth. The cancer typically spreads to lymph nodes, bones, or other organs while maintaining its sensitivity to hormone therapy. This form of prostate cancer represents a stage where the disease has become metastatic but remains responsive to treatments that reduce testosterone levels in the body.